--- title: "Hong Kong stock movement: GENFLEET-B rises 18.65%, with clear capital flow, market sentiment triggers volatility attention" type: "News" locale: "en" url: "https://longbridge.com/en/news/282614747.md" description: "GENFLEET-B rose 18.65%; Innovent Biologics rose 0.29%, with a transaction amount reaching HKD 173 million; BeiGene fell 0.80%, with a transaction amount reaching HKD 158 million; CanSino Biologics rose 0.94%, with a transaction amount reaching HKD 151 million; Kelun-Biotech fell 0.37%, with a market value of HKD 113.2 billion" datetime: "2026-04-14T02:07:49.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282614747.md) - [en](https://longbridge.com/en/news/282614747.md) - [zh-HK](https://longbridge.com/zh-HK/news/282614747.md) --- # Hong Kong stock movement: GENFLEET-B rises 18.65%, with clear capital flow, market sentiment triggers volatility attention **Hong Kong Stock Movement** GENFLEET-B rose by 18.65%, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Stocks with High Trading Volume in the Industry** Innovent Biologics rose by 0.29%, with a trading volume of HKD 173 million, and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. BeiGene fell by 0.80%. Based on recent news, 1. On April 13, BeiGene announced that based on the research results of the combination therapy with Bahezuan®, the Center for Drug Evaluation of the National Medical Products Administration of China has accepted the new indication marketing authorization applications for Zhenidatuzumab and Bahezuan®, both intended for first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma. This news had a positive impact on the stock price but did not fully offset other negative factors. 2. On April 13, the earnings validated the feasibility of the business model but did not resolve the issue of a unified global valuation anchor. In the short term, factors such as pricing tug-of-war in three regions, adjustments in shareholder structure, and reliance on single products will continue to suppress stock price performance; in the long term, only sustained high growth, realization of a second growth curve, and overall improvement in profit quality can break the valuation paradox and find a stable valuation anchor in the global coordinate system. These factors have put pressure on the stock price. 3. On April 13, from an industry perspective, BeiGene's predicament is not an isolated case but a common proposition in the globalization process of Chinese innovative drugs: when local leaders are placed in a fully competitive global market, their value will ultimately return to operational quality and long-term competitiveness, priced collectively by global capital. The overall challenges in the industry have also negatively impacted the stock price. The innovative drug industry faces globalization challenges. Kangfang Biotech rose by 0.94%. Based on recent key news: 1. On April 11, Kangfang Biotech announced that it will accelerate the clinical transformation of ADC, TCE, siRNA, and other platform products, promoting the company's transformation from a leading dual-antibody company in China to a globally competitive biopharmaceutical enterprise. This clear strategic goal has enhanced market confidence in its future development, leading to a rise in stock price. 2. On April 14, senior securities analyst Peng Weixin suggested gradually accumulating Kangfang Biotech shares around HKD 135, with a target price of HKD 150. This suggestion has attracted market attention and driven the stock price up. 3. No other significant news recently. The competition in the biopharmaceutical industry is intensifying, and policy changes need to be monitored. **Stocks with High Market Capitalization in the Industry** Kanglongda Biotech fell by 0.37%. Based on recent key news: 1. On April 14, Kanglongda Biotech's sac-TMT was approved in China for four indications, two of which have been included in medical insurance. This progress may enhance the company's market share in the treatment of breast cancer and non-small cell lung cancer, driving stock price volatility 2. On April 14th, Kelun-Biotech announced its 9 registration clinical studies conducted in China, as well as 17 global Phase III clinical studies led by Merck. The progress of these studies may affect the company's future market performance. 3. On April 14th, Kelun-Biotech disclosed updates on its Phase II studies for ovarian cancer and cervical cancer. The results of these studies may impact the company's competitiveness in the relevant treatment areas. The biopharmaceutical industry is active in the research and development of innovative drugs ### Related Stocks - [02595.HK](https://longbridge.com/en/quote/02595.HK.md) ## Related News & Research - [Biopharmaceutical firm Parabilis Medicines files for US IPO](https://longbridge.com/en/news/286967895.md) - [NorthPalm Capital Launches as AI-Augmented Investment Company | SCYRF Stock News](https://longbridge.com/en/news/286914222.md) - [Trade Spotlight: How should you trade Indus Towers, NMDC, Max Healthcare, BSE, KEI Industries, and others on May 15?](https://longbridge.com/en/news/286488386.md) - [Release according to article 135 section 2 BörseG](https://longbridge.com/en/news/286754366.md) - [New York Governor Signs Bills To Preserve Mandatory Vaccines](https://longbridge.com/en/news/286947583.md)